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The serpins (serine proteinase inhibitors) are a superfamily of
proteins (350–500 amino acids in size) that fold into a conserved
structure and employ a unique suicide substrate-like inhibitory
mechanism. The serpins were last reviewed in 1994 (1). More
recent studies show: 1) an expanded distribution within the king-
doms of metazoa and plantae, as well as certain viruses, 2) a
surprising effect on the covalently bound target proteinase, and 3)
novel biochemical and biological functions.
Most serpins inhibit serine proteinases of the chymotrypsin fam-
ily. However, cross-class inhibitors have been identified. The viral
serpin CrmA and, to a lesser extent, PI9 (SERPINB9) inhibit the
cysteine proteinase, caspase 1 (2), and SCCA11 (SERPINB3) neu-
tralizes the potent papain-like cysteine proteinases, cathepsins L,
K, and S (3). In addition, several members no longer function as
proteinase inhibitors but perform other roles such as hormone
transport (thyroid-binding globulin (SERPINA6), corticosteroid-
binding globulin (SERPINA7)), and blood pressure regulation (an-
giotensinogen (SERPINA8)) (1).
Data base searching provides evidence for 500 serpins, with
full-length coding sequences known or predicted for about one-half
of those (4). A phylogenetic analysis divides serpins into 16 clades
(see Supplemental Data, Table A) and 10 highly diverged “orphans”
(4). These data facilitate the construction of a consistent expanda-
ble nomenclature (see Supplemental Data for Serpin Nomenclature
Guidelines, Table B).
The completed DNA sequences of several organisms have yielded
insight into the complexity of the family. The Caenorhabditis el-
egans, Drosophila melanogaster, and Arabidopsis thaliana ge-
nomes encode for 20,000, 13,000, and 25,000 genes, respectively.
However, these three species harbor 9, 32, and 13 serpin genes,
respectively. The nonlinear relationship among the number of ser-
pin genes, relative to the total gene number, suggests that at least
a subset of serpins has evolved divergent functions despite a strik-
ing degree of sequence and structural conservation.
Serpin Structural Features: Conformations, Inhibitory
Mechanism, and Polymerization
Serpin Conformations—Serpins adopt a metastable conformation
that is required for their inhibitory activity (5). This conformation
consists of a conserved secondary structure comprised of -sheets A,
B, and C and at least 7 -helices (most typically have 9, lettered A–I;
Fig. 1A). The RSL, which contains the proteinase recognition site, is
an exposed, flexible stretch of 17 residues tethered between
-sheets A and C. Serpins can undergo major structural rearrange-
ments that involve alternative conformations for the RSL, -sheet A,
and the attached strand 1 of -sheet C. Considering only intramolec-
ular structural changes, serpins can convert to the more stable latent
form (Fig. 1B). The RSL inserts into the middle of -sheet A to give a
fully antiparallel -sheet, and s1C is extracted from -sheet C to
provide an exposed “return” from the bottom of the serpin. Serpins in
the latent conformation are noninhibitory but can be converted back
to the active state by denaturation and refolding. The Tm for unfold-
ing of latent PAI1 (SERPINE1) is 17 °C higher than that for the
native state (reviewed in Ref. 6). The most stable state for inhibitory
serpins is the RSL-cleaved form, in which the RSL has fully inserted
into -sheet A, as in the latent conformation, but without the need to
extract s1C from -sheet C (Fig. 1C). Estimates of the Tm for unfold-
ing of such conformations are 120 °C, compared with 60 °C for the
native state (7).
The most informative serpin structures, from a mechanistic
viewpoint, are those of a Michaelis complex between Serpin 1 and
trypsin (Fig. 1D) and of a covalent complex between 1AT (SER-
PINA1) and trypsin (8) (Fig. 1E). This latter structure represents
the proteinase after it has been kinetically trapped in the acyl-
enzyme intermediate that forms normally along the peptide bond
cleavage pathway. Whereas the bound serpin is almost indistin-
guishable from that of the RSL-cleaved form (Fig. 1C), the protein-
ase is grossly distorted (see below).
Serpin Inhibitory Mechanism—Serpins inhibit serine protein-
ases by an irreversible suicide substrate mechanism when the
interaction proceeds down the inhibitory arm of a branched path-
way (Fig. 2) (6). In the inhibitory pathway, the proteinase initially
forms a noncovalent Michaelis-like complex (Fig. 1D) through in-
teractions with residues flanking the scissile bond (P1–P1). Attack
of the active site serine on the scissile bond leads to a covalent ester
linkage between Ser-195 of the proteinase and the backbone car-
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bonyl of the P1 residue and cleavage of the peptide bond (6). It is
likely that only at this stage, with removal of the restraint, does the
RSL start to insert into -sheet A and transport the covalently
bound proteinase with it. Upon complete loop insertion the protein-
ase is translocated by over 70 Å, and its active site is distorted (Fig.
1E). The alignment of the active site catalytic triad is altered by as
much as 3 Å, and the P1 side chain is removed from the S1 pocket.
Also, 40% of the body of the proteinase shows no traceable electron
density. Proteinase distortion and hence inactivation results from
compression of the proteinase against the base of the serpin as a
consequence of the inserted RSL being just the right length. The
energy needed to effect the distortion may come from the much
greater stability of the cleaved loop-inserted conformation com-
pared with the native-like conformation. The net result of this
conformational rearrangement is kinetic trapping of the acyl inter-
mediate due to slowing of the deacylation steps of the normal
substrate reaction by 6–8 orders of magnitude (k5 in Fig. 2). Be-
cause of the small values for k5 (complex t1⁄2  hours to weeks),
serpin-proteinase complexes in vivo would bind to their receptors
and be cleared (complex t1⁄2  minutes) long before significant
complex decay could occur.
The point in transit where the enzyme activity is reduced suffi-
ciently to commit the intermediate to the kinetic trap is not known
but in part contributes to the branched nature of the pathway and the
ultimate fate of the complex. If, for example, RSL movement is
impeded, the enzyme may successfully complete the deacylation step
and escape before it is irreversibly trapped. This noninhibitory path-
way yields an active proteinase and a cleaved, inactive serpin. The
ratio of serpin products (complex versus cleaved) thus reflects a
competition between the rate of ester hydrolysis (k3 in Fig. 2) and
that of loop insertion (k4 in Fig. 2) to the point of proteinase distor-
tion. This ratio is signified also by the stoichiometry of inhibition,
which is defined as (k3  k4)/k4, i.e. the number of moles of serpin
needed to inhibit 1 mol of proteinase as a kinetically trapped
complex.
This mechanism accounts for the requirements for effective inhi-
bition by serpins, which include a critical RSL length, appropriate
residues within the loop that are compatible with rapid and favorable
burial into -sheet A, and the presence of Ser in the proteinase active
site (6). Such a mechanism is adaptable to the inhibition of cysteine
proteinases by serpins, with the difference being that the kinetically
trapped intermediate is a thiol ester rather than an oxy ester. The
detection of CrmA, a serpin that inhibits cysteine proteinases of the
caspase family, in the loop-inserted cleaved conformation supports
the feasibility of a common inhibitory mechanism (9), whereas the
detection of an SDS-stable complex between SCCA1 and cathepsin S
(a cysteine proteinase of the papain family) provides evidence for the
formation of a stable, covalent thiol ester-type linkage (3). The few
convincing reports of reversible inhibition, such as of single-chain
uPA by PCI (SERPINA5) (10) or of chymotrypsin by 2AP (SER-
PINF2) (11) may represent special cases in which unusual stabiliza-
tion of the initial noncovalent Michaelis-like complex blocks progres-
sion to the substrate reaction.
Dimerization and Higher Order Polymer Formation—A negative
consequence of the need for a metastable conformation in the active
state is that natural mutations, either alone or in combination with
environmental factors, can promote inappropriate loop insertion.
When this occurs between the RSL of one molecule and the -sheet
of another, dimers and higher order oligomers can result. Either
through depletion of active serpin or through pathological effects of
the polymers themselves, such aggregate formation can lead to
disease. The best characterized examples are the emphysema (ser-
pin depletion) and cirrhosis (intracellular inclusions) associated
with loop-sheet polymers of the Z or S variants of 1AT (12) (see
Supplemental Data, Fig. A) and the dementia associated with
neuroserpin (SERPINI1) inclusion bodies (see below).
New Serpins and Novel Functions
Understanding the biologic function of serpins remains an ongo-
ing challenge. For example, the biologic functions for many of the
human serpins involved in the clotting and fibrinolytic cascades are
FIG. 2. Fate of the serpin and proteinase complex via the
branched pathway. The serpin (I) inhibition of proteinase (E) pro-
ceeds via an initial noncovalent, Michaelis-like complex (EI) that in-
volves no conformational change within the proteinase or the body of
the serpin. Subsequent peptide bond hydrolysis results in an acyl-
enzyme intermediate (EI#) that progresses to either a kinetically
trapped loop-inserted covalent complex (EI, inhibitory pathway) or a
cleaved serpin (I*) and free proteinase (noninhibitory or substrate path-
way). The serpin body is in yellow. Free serine proteinase is in green and
covalently bound proteinase is in red. Reprinted from Ref. 41 with
permission from Cold Spring Harbor Laboratory.
FIG. 1. Serpin structures. From left to right: A, native 1AT (Protein Data Bank (PDB) entry 1QLP); B, latent ATIII (PDB entry 2ANT); C, cleaved 1AT
(PDB entry 7API); D, Michaelis complex between Serpin 1 (Alaserpin from Manduca sexta) and trypsin (PDB entry 1I99 (S. Ye, A. Cech, R. Belmares, E. J.
Goldsmith, R. Bergstrom, D. Corey, and M. Kanost, submitted for publication)); and E, covalent complex between 1AT and trypsin (PDB entry 1ezx). In all
structures the A-sheet is in red, the B-sheet is in green, the C-sheet is in yellow, and the RSL(RCL) is in purple. The helices are in gray and are labeled on
the structure of native 1AT. Trypsin is shown as a cyan coil.
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well documented. However the role of human serpins in some other
types of biologic processes awaits further validation (Fig. 3).
Ov-serpins (B Clade)—In 1993 amino acid similarities among
chicken ovalbumin (ov), PAI2 (SERPINB2), and MNEI (SERPINB1)
led to the identification of a subgroup of the serpin superfamily (13).
The N and C termini of the ov-serpins are shorter than the prototyp-
ical serpin 1AT, and they also lack a classical secretory signal
peptide. At present, there are 13 human ov-serpins (see Supplemen-
tal Data, Table B). They map to 6p25 and 18q21 and fall into two
classes based on a single difference in gene structure (14). Like
ovalbumin, many of the 18q21 serpin genes have an exon encoding a
polypeptide loop between helices C and D (CD loop) that may con-
tribute to accessory functions.
Unlike ovalbumin itself, most ov-serpins reside intracellularly
with a cytoplasmic or nucleocytoplasmic distribution. However,
several ov-serpins (PAI2, megsin (SERPINB7), MNEI, maspin
(SERPINB5), and the SCCAs (SERPINB3 and -4)) may function
extracellularly as they are released from cells under certain condi-
tions. Release may be facilitated by an embedded, noncleaved hy-
drophobic N-terminal signal sequence and appears to involve both
conventional and non-endoplasmic reticulum-Golgi secretory path-
ways (15). Regardless of how ov-serpins are released from cells,
those with RSL cysteine or methionine residues are susceptible to
oxidative inactivation and are likely to have a limited half-life in
the extracellular milieu.
With the possible exception of maspin, all human ov-serpins are
functional, competitive inhibitors of serine or cysteine proteinases.
Several members of the group inhibit more than one proteinase, and
dual reactive sites (utilization of more than one P1 residue) have been
described for PI6 (SERPINB6), PI8 (SERPINB8), PI9, SCCA1,
SCCA2, and MNEI (for example see Ref. 16). However, the CD loops
of the ov-serpins have the potential to interact with other proteins.
For example, the CD loop of PAI2 is required for its cell survival
function (17) and is a target for transglutamination (18). Bomapin
(SERPINB10; like the chicken ov-serpin, MENT, see below) carries a
nuclear localization signal in its CD loop that presumably interacts
with a nuclear importin (19).
The physiological functions of ov-serpins are still emerging. PAI2
may play a role in the regulation of extracellular matrix remodeling
through the inhibition of uPA, as high PAI2 and low uPA levels
correlate with a positive prognosis in breast cancer (20). Also, PAI2
may have a structural role inside some cells (perhaps keratino-
cytes) as suggested by its ability to spontaneously polymerize and
undergo transglutamination (21).
Many ov-serpins reside in proteinase-secreting cells (22). For
example, PI9, a potent inhibitor of granzyme B, is also present in
cytotoxic lymphocytes. Because PI9 can protect cells against gran-
zyme B-mediated apoptosis, it probably protects cytotoxic lympho-
cytes from autodestruction due to misdirected granzyme B. A sim-
ilar cytoprotective role can be envisaged for PI6, PI8, MNEI, PAI2,
and the SCCAs. In addition, endogenous or exogenous ov-serpins
may protect bystander cells and tissue from proteolytic damage.
Studies in rats show that recombinant MNEI delivered to the
airways prevents lung injury by neutrophil proteinases and point
to its potential in treating inflammatory lung disease (23).
The ability of many ov-serpins to inhibit more than one protein-
ase and their presence in epithelial cells suggest that they play a
role in barrier function or host defense against microbial or viral
proteinases. For example, PI9 inhibits Bacillus subtilisin, and PI8
inhibits furin, a subtilisin-related enzyme (24, 25). Additional func-
tions of ov-serpins include the regulation of: 1) cell growth or
differentiation, as exemplified by the role of megsin in megakaryo-
cyte differentiation (26), 2) tumor cell invasiveness and motility, as
shown by the inhibitory role of maspin in breast and prostate
tumors (27), and 3) angiogenesis (see below).
MENT—Grigoryev et al. (28) isolated a novel serpin, MENT,
from the nuclei of terminally differentiated chicken hematopoietic
cells. MENT is an ov-serpin with a CD loop that contains a nuclear
localization signal, a lamin-like chromatin binding domain, and an
A-T hook DNA binding motif. The molecule has a relatively high pI
(9 versus 5–6.5 for that of other serpins) with the majority of
positive charges clustering near the CD loop. Thus, MENT appears
to utilize the CD loop to bind tightly to nucleosomes with an
apparent stoichiometry of 2:1. MENT is the major non-histone
chromatin protein in differentiated nuclei and is concentrated in
the heterochromatin. MENT induces higher order chromatin com-
paction when it is expressed ectopically in cells or added to isolated
nuclei in vitro. Although MENT contains a viable RSL, target
proteinases have yet to be identified.
Neuroserpin—Neuroserpin, which inhibits tPA, uPA, trypsin,
and nerve growth factor  in vitro, is secreted from neurons, glia,
and neuroendocrine cells (29). Neuroserpin may play a therapeutic
role in protecting the brain from ischemic injury. In a rat stroke
model, neuroserpin expression was increased in neurons located
within the ischemic penumbra, and intracerebral injections of the
protein reduced the stroke volume by 64% and the number of
apoptotic cells by 50% (30).
In a familial form of early onset dementia and encephalopathy,
toxic intraneuronal inclusions contained neuroserpin polymers.
Molecular analysis in two pedigrees revealed mutations (S49P and
S52R) in the B-helix (31). These mutations are similar to that seen
in 1AT Siiyama, in which an S53F mutation facilitates premature
opening of -sheet A and the formation of loop-sheet polymers. In
turn, these polymers precipitate and accumulate in the cytoplasm
until normal cellular function is disrupted.
Serpins and Alzheimer’s Disease—ACT (SERPINA3) and, to a
lesser extent, other serpins are found within the fibrillary amyloid
plaques of brains from patients with Alzheimer’s disease, one of the
most common forms of dementia (reviewed in Ref. 32). Although
the pathogenesis of this disorder is complex, the extracellular ac-
cumulation of A-(1–42)-peptide fibrils may be neurotoxic by bind-
ing to low density lipoprotein receptors and interfering with cho-
lesterol metabolism. ACT appears to facilitate fibril formation by
serving as a chaperone for the A-(1–42)-peptide. The peptide
inserts into B-sheets A and C of ACT in which it assumes a
-strand conformation. Upon RSL cleavage, A-(1–42)-peptide is
released into the extracellular milieu, in which the -strand pep-
tide is now more prone to polymerize.
FIG. 3. Biological functions of human serpins. Human serpins are
involved in a diversity of biologic functions (italics). For some serpins (red
type), their biologic functions appear to be related directly to proteinase
inhibition. For others (green type), their activity does not require proteinase
inhibition, or their role in the biologic process has not been defined.
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Pigment Epithelium-derived Factor and Other Serpins That May
Interfere with Angiogenesis—PEDF (SERPINF1) is a secreted, non-
inhibitory serpin that was isolated from retinal pigment epithelial
cells but is also detected in liver, lung, heart, spleen, brain, and
testis (6). This factor promotes the survival and differentiation of
retinal photoreceptors, cerebellar granule neurons, and spinal mo-
tor neurons. Dawson et al. (33) show that PEDF inhibits neovas-
cularization of the rat cornea and endothelial cell migration in
vitro. In the cell migration assay, PEDF was as potent as other
angiogenesis inhibitors such as angiostatin, endostatin, and throm-
bospondin-1. Moreover, PEDF antagonized the effects of the angio-
genesis inducers, VEGF, basic fibroblast growth factor, platelet-
derived growth factor, and interleukin 8. PEDF expression in the
eye increases with rising oxygen tension (just the opposite of
VEGF). Thus, VEGF and PEDF appear to counter-regulate blood
vessel growth in the eye by enhancing and antagonizing angiogen-
esis during hypoxic and hyperoxic conditions, respectively.
PAI1, maspin, and RSL-cleaved ATIII (SERPINC1) have been
shown to interfere with angiogenesis in various assay systems
(34–36). However, it has yet to be determined whether any of these
molecules are truly involved in the physiologic or pathologic regu-
lation of blood vessel growth.
Serpins and Host Defense—A loss of function mutation in the
Drosophila serpin gene, Spn43Ac, leads to the necrotic phenotype
and constitutive expression of the antifungal peptide, drosomycin
(37). Normally activation of the antifungal pathway involves pro-
teolytic cleavage of the Toll (Tl) ligand, spaetzle (spz). In turn, Tl
activation leads to an increase in both Spn43Ac and drosomycin
synthesis via the Rel-Cactus (NF-B-IB-like) pathway. Spn43Ac
appears to act in a negative feedback loop by inhibiting proteinases
that activate spz. Thus, the constitutive expression of drosomycin
and the necrotic phenotype appear to be secondary to unregulated
proteolytic activity.
Plant Serpins—The function of these proteins remains obscure.
Several studies show that plant serpins are capable of inhibiting
serine proteinase targets (38). However, with the exception of a
chymotrypsin-like proteinase identified in ragweed pollen, conven-
tional serine proteinase targets are absent in plants. BLAST
searches of the A. thaliana genome using the sequence of trypsin as
a probe failed to identify any classical chymotrypsin-like homo-
logues. In vivo studies by Yoo et al. (39) show that up-regulation of
the Cucurbita maxima Phloem Serpin-1 (CmPS-1) correlates
closely with the inability of the piercing sucking aphid Myzus
persicae to survive and reproduce on these plants, suggesting a role
for plant serpins in host defense.
Targeted Deletions of Mouse Serpins—Several murine ortho-
logues of human serpins have been deleted by targeted mutation in
embryonic stem cells. Some of these mutations have failed to reveal
an overt phenotype, whereas others show physiologic and struc-
tural alterations as well as embryonic lethality (see Supplemental
Data, Table C).
Viral Serpins—Serpins are found within a number of genera
within the subfamilies of the vertebrate poxviruses and the gam-
maherpesviruses (see Supplemental Data, Table D). To date, none
of the serpins are required for virus growth in cell culture. Within
the vertebrate poxvirus genera, each Orthopoxvirus (variola, vac-
cinia, and rabbitpox) encodes three highly conserved serpins,
SPI-1, SPI-2/CrmA, and SPI-3. Each targets different types of
proteinases (Table D). The prototypic member of the Leporipoxvi-
rus genus (myxoma virus) also encodes three serpins, SERP1–3.
Within the Avipoxvirus genus, the fowlpox virus genome contains 5
serpin genes (Table D). Other vertebrate poxviruses (molluscum
contagiosum and ORF viruses) lack serpin genes. All genera of
poxviruses encode serpins with putative Asp P1 residues, and the
leporipoxviruses, orthopoxviruses, and fowlpox viruses all have a
member with a putative Arg P1 residue (Table D). Only the or-
thopoxviruses have a serpin with a Phe at the putative P1 site. For
more information on Orthopoxvirus and Leporipoxvirus serpins see
Supplemental Data.
Conclusions
The serpins are a superfamily of genes that are distributed
throughout the metazoa and plantae kingdoms. Serpin family mem-
bers are identified by a conserved tertiary structure and a unique
suicide substrate-like inhibitory mechanism. Serpins reside both in-
tracellularly and extracellularly and are involved in a diverse set of
biologic functions that extend beyond the ability of these molecules to
irreversibly inhibit target proteinases. The study of serpin function
using different biological platforms, such as the nematode (40) and
fruit fly, should help identify the role that these molecules play in
development, homeostasis, and host defense.
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